Aptatek Biosciences

Aptatek is developing cutting edge technologies for portable disease management devices that will improve patient compliance, wellness, and overall quality of life. To start, they are focusing on Phenylketonuria (PKU), a disease where patients must closely monitor their phenylalanine levels for their entire lifetimes or face severe health challenges. Currently, PKU patients have no choice but to visit a hospital or mail in blood samples to a central lab. Aptatek's proprietary aptamer design strategies and patented sequences create the opportunity for novel tests and new test strategies. The core technology was developed in the laboratories of Dr. Milan Stojanovic and Dr. Tilla Worgall, faculty members at Columbia University Medical Center. It is based on DNA aptamer sequences that detect small molecule biomarkers which cannot be detected by antibodies. The sensitivity and specificity matches laboratory instruments including mass spectrometry. Learn more at https://aptatek.com/

• Employees6
• Founded2008
• Total Funding$4000000